Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 1, 2007, Pages 25-34

  Olive, Colleen ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Group A Streptococcus; M protein; Rheumatic fever; Rheumatic heart disease; Subunit vaccine; Synthetic peptide vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; C5A PEPTIDASE; CARBOHYDRATE DERIVATIVE; CYSTEINE PROTEINASE; FIBRONECTIN BINDING PROTEIN 1; FIBRONECTIN BINDING PROTEIN 54; GLUTAMINYLALANYLGLUTAMYLASPARTYLLYSYLVALYLLYSYLGLUTAMINYLSERYL ARGINYLGLUTAMYLALANYLLYSYLLYSYLGLUTAMINYLVALYLGLUTAMYLLYSYL ALANYLLEUCYLLYSYLGLUTAMINYLLEUCYLGLUTAMYLASPARTYLLYSYLVALYLGLUTAMINE; GLUTAMYLLYSYLGLUTAMINYLISOLEUCYLSERYLASPARTYLALANYLSERYLARGINYLGLUTAMINE; IMMUNOLOGICAL ADJUVANT; LEUCYLASPARTYLALANYLSERYLARGINYLGLUTAMYLALANYLLYSYLLYSYL GLUTAMINYLVALYLGLUTAMYLLYSYLASPARTYLLEUCYLALANYLASPARAGINYLLEUCYL THREONYLALANYLGLUTAMYLLEUCINE; LIPOTEICHOIC ACID; LYSYLGLUTAMINYLVALYLGLUTAMYLLYSYLASPARTYLLEUCYLALANYL ASPARAGINYLLEUCYLTHREONYLALANYLGLUTAMYLLEUCYLASPARTYLLYSYLVALYLLYSYL GLUTAMYLGLUTAMYLLYSYLGLUTAMINE; LYSYLGLUTAMYLGLUTAMINYLLYSYLSERYLLYSYLGLUTAMINYLASPARAGINYL ISOLEUCYLGLYCYLALANYLLEUCYLLYSYLGLUTAMINYLGLUTAMYLLEUCYLALANYLLYSYLLYSYL ASPARTYLGLUTAMYLALANYLASPARAGINYLLYSYLISOLEUCYLSERYLASPARTYLALANYLSERYLARGININE; LYSYLGLYCYLLEUCYLARGINYLARGINYLASPARTYLLEUCYLASPARTYLALANYL SERYLARGINYLGLUTAMYLALANYLLYSYLLYSYLGLUTAMINYLLEUCYLGLUTAMYLALANYL GLUTAMYLHISTIDYLGLUTAMINYLLYSYLLEUCYLGLUTAMYLGLUTAMYLGLUTAMINE; M PROTEIN; PEPTIDE; PILI PROTEIN; PROTEIN M1; RECOMBINANT VACCINE; SERUM OPACITY FACTOR; SERYLARGINYLLYSYLGLYCYLLEUCYLARGINYLARGINYLASPARTYLLEUCYL ASPARTYLALANYLSERYLARGINYLGLUTAMYLALANYLLYSYLLYSYLGLUTAMINYLVALYLGLUTAMYLLYSINE; SERYLLYSYLGLUTAMINYLASPARTYLISOLEUCYLGLYCYLALANYLLEUCYLLYSYL GLUTAMINYLGLUTAMYLLEUCYLALANYLLYSYLLYSYLASPARTYLGLUTAMYLGLYCYLASPARAGINYLLYSINE; STREPTOCOCCUS ANTIGEN; STREPTOCOCCUS VACCINE; STREPTOLYSIN S; SUBUNIT VACCINE; SURFACE PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLLYSYLGLUTAMYLGLUTAMYLLYSYLGLUTAMINYLISOLEUCYLSERYL ASPARTYLALANYLSERYLARGINYLGLUTAMINYLGLYCYLLEUCYLARGINYLARGINYL ASPARTYLLEUCYLASPARTYLALANINE; VIRULENCE FACTOR;

AMINO ACID SEQUENCE; AUTOIMMUNITY; BACTERIAL STRAIN; CAUSE OF DEATH; CLINICAL TRIAL; DEVELOPED COUNTRY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SCREENING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNITY; IMMUNIZATION; MOLECULAR MIMICRY; MORBIDITY; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROVOCATION TEST; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SEQUENCE HOMOLOGY; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; HUMANS; MOLECULAR SEQUENCE DATA; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS SP. 'GROUP A';

EID: 33947307470     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Cunningham MW: Pathogenesis of group A streptococcal infections. Clin Microbiol Rev (2000) 13(3):470-511. • Provides a comprehensive review of GAS infections, including suppurative and non-suppurative sequelae, host-pathogen interactions, and potential mechanisms of disease pathogenesis.
2. Bisno AL: Group A streptococcal infections and acute rheumatic fever. N Eng J Med (1994) 325(11):783-793.
3. Carapetis JR, Wolff DR, Currie BJ: Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust (1996) 164(3):146-149.
4. Nguyen L, Levy D, Ferroni A, Gehanno P, Berche P: Molecular epidemiology of Streptococcus pyogenes in an area where acute pharyngotonsillitis is endemic. J Clin Microbiol (1997) 35(8):2111-2114.
5. Bronze MS, Dale JB: The reemergence of serious group A streptococcal infections and acute rheumatic fever. Am J Med Sci (1996) 311(1):41-54.
6. Carapetis JR, Steer AC, Mulholland EK, Weber M: The global burden of group A streptococcal diseases. Lancet Infect Dis (2005) 5(11):685-694. •• This report reviews recent population-based data to estimate the global burden of GAS diseases. It provides information on the prevalence of RHD and incidence of RF, and mortality from acute RF and RHD, in addition to other RHD-related morbidity and mortality, such as stroke. Information on disease burden is also presented for invasive GAS diseases, acute post-streptococcal glomerulonephritis, pyoderma and pharyngitis.
7. Martin DR, Sriprakash KS: Epidemiology of group A streptococcal disease in Australia and New Zealand. Recent Adv Microbiol (1996) 4:1-40.
8. Stollerman GH: Rheumatic fever. Lancet (1997) 349(9056):935-942.
9. Vijakumar M, Narula J, Reddy KS, Kaplan EL: Incidence of rheumatic fever and prevalence of rheumatic heart disease in India. Int J Cardiol (1994) 43(3):221-228.
10. Pichichero ME: Group A β-hemolytic streptococcal infections. Pediatr Rev (1998) 19(9):291-302.
11. Centers for Disease Control: Acute rheumatic fever among army trainees Fort Leonard Wood, Missouri, 1987-1988. MMWR (1988) 37(34):519-522. http://www.cdc.gov/mmwR/preview/mmwrhtml/00001088. htm
12. Hasty DL, Ofek I, Courtney HS, Doyle RJ: Multiple adhesins of streptococci. Infect Immun (1992) 60(6):2147-2152.
13. Whitnack E, Beachey EH: Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci. J Clin Invest (1982) 69(4):1042-1045.
14. Raeder R, Boyle MDP: Properties of IgG-binding proteins expressed by Streptococcus pyogenes isolates are predictive of invasive potential. J Infect Dis (1996) 173(4):888-895.
15. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA: Antiphagocytic activity of streptococcal M protein: Selective binding of complement control protein factor H. Proc Natl Acad Sci USA (1988) 85(5):1657- 1661.
16. McKay FC, McArthur JD, Sanderson-Smith ML, Gardam S, Currie BJ, Sriprakash KS, Fagan PK, Towers RJ, Batzloff MR, Chhatwal GS, Ranson M, Walker MJ: Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. Infect Immun (2004) 72(1):364-370.
17. Molinari G, Chhatwal GS: Streptococcal invasion. Curr Opin Microbiol (1999) 2(1):56-61.
18. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L: Intracellular reservoir of Streptococcus pyogenes in vivo: A possible explanation for recurrent pharyngotonsillitis. Laryngoscope (1997) 107(5):640-647.
19. Dale JB, Baird RW, Courtney HS, Hasty DL, Bronze MS: Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J Infect Dis (1994) 169(2):319-323.
20. Yokoyama Y, Harabuchi Y: Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol (2002) 63(3):235-241.
21. Schulze K, Medina E, Talay SR, Towers RJ, Chhatwal GS, Guzman CA: Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect Immun (2001) 69(1):622-625.
22. Guzman CA, Talay SR, Molinarai G, Medina E Chhatwal GS: Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis (1999) 179(4):901-906.
23. Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi K, Totsuka K, Hamada S: Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun (2001) 69(2):924-930.
24. Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf DH, Schlievert PM: Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun (2000) 68(9):5011-5017.
25. McCormick JK, Tripp TJ, Olmsted SB, Matsuka YV, Gahr PJ, Ohlendorf DH, Schlievert PM: Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol (2000) 165(4):2306-2312.
26. Kapur V, Maffei JT, Greer RS, Li L-L, Adams GJ, Musser JM: Vaccination with streptococcal extracellular cysteine protease (interleukin-1β convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog (1994) 16(6):443-450.
27. Dale JB, Washburn RG, Marques MB, Wessels MR: Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun (1996) 64(5):1495-1501.
28. Sabharwal H, Michon F, Nelson D, Dong W, Fuchs K, Manjarrez RC, Sarkar A, Uitz C, Viteri-Jackson A, Suarez RS, Blake M, Zabriskie JB: Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis (2006) 193(1):129-135.
29. Courtney HS, Hasty DL, Dale JB: Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun (2003) 71(9):5097-5103.
30. Nelson D, Loomis L, Fischetti VA: Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA (2001) 98(7):4107-4112.
31. Dale JB, Chiang EY, Hasty DL, Courtney HS: Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect Immun (2002) 70(4):2166- 2170.
32. Dale JB, Chiang EY, Liu S, Courtney HS, Hasty DL: New protective antigen of group A streptococci. J Clin Invest (1999) 103(9):1261-1268.
33. Ji Y, Carlson B, Kondagunta A, Cleary PP: Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun (1997) 65(6):2080-2087.
34. Cleary PP, Matsuka YV, Huynh T, Lam H, Olmsted SB: Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine (2004) 22(31-32):4332-4341.
35. Sanderson-Smith M, Batzloff M, Sriprakash KS, Dowton M, Ranson M, Walker MJ: Divergence in the plasminogen-binding group A streptococcal M protein family: Functional conservation of binding site and potential role for immune selection of variants. J Biol Chem (2006) 281(6):3217-3226.
36. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, Manetti AGO, Maggi T, Taddei AR, Grandi G, Telford JL: Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci USA (2005) 102(43):15641-15646.
37. Fischetti VA: Streptococcal M protein. Sci Am (1991) 264(6):58-65.
38. Robinson JH, Kehoe MA: Group A streptococcal M protein: Virulence factors and protective antigens. Immunol Today (1992) 13(9):362-367.
39. Fischetti VA: Streptococcal M protein: Molecular design and biological behavior. Clin Microbiol Rev (1989) 2(3):285-314.
40. Dale JB, Beachey EH: Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein. J Exp Med (1986) 163(5):1191-1202.
41. Pruksakorn S, Galbraith A, Houghten RA, Good MF: Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol (1992) 149(8):2729-2735.
42. Guilherme L, Cunha-Neto E, Tanaka AC, Dulphy N, Toubert A, Kalil J: Heart-directed autoimmunity: The case of rheumatic fever. J Autoimmun (2001) 16(3):363-367.
43. Froude J, Gibofsky A, Buskirk DR, Khanna A, Zabriskie JB: Cross-reactivity between Streptococcus and human tissue: A model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol (1989) 145:5-26.
44. Cunningham MW, McCormack JM, Fenderson PG, Ho M, Beachey EH, Dale JB: Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J Immunol (1989) 143(8):2677-2683.
45. Cunningham MW, Antone SM, Smart M, Liu R, Kosanke S: Molecular analysis of human cardiac myosin-cross reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun (1997) 65(9):3913-3923.
46. Dale JB, Beachey EH: Multiple, heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med (1985) 161(1):113-122.
47. Pruksakorn S, Currie B, Brandt E, Phornphutkul C, Hunsakunachai S, Manmontri A, Robinson JH, Kehoe MA, Galbraith A, Good MF: Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol (1994) 6(8):1235-1244.
48. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW: Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun (2001) 69(6):4072-4078. • A rat model of streptococcal-induced autoimmune valvulitis was developed in which rats were injected subcutaneously with GAS M protein. The results of this study suggest that the M protein contains epitopes that are cross-reactive with heart antigens, and that these may be stimulated in vivo, resulting in pathology.
49. Huber SA, Cunningham MW: Streptococcal M protein peptide with similarity to myosin induces CD4+ T cell-dependent myocarditis in MRL/++ mice and induces partial tolerance against coxsakieviral myocarditis. J Immunol (1996) 156(9):3528-3534.
50. El-Demellawy M, El-Ridi R, Guirguis NI, Adel Alim M, Kotby A, Kotb M: Preferential recognition of human myocardial antigens by T lymphocytes from rheumatic heart disease patients. Infect Immun (1997) 65(6):2197-2205.
51. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PMA, Assis RV, Pedra F, Neumann J, Goldberg A, Patarroyo ME, Pileggi F, Kalil J: Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation (1995) 92(3):415-420. • This paper presents strong evidence to support a role for cross-reactive T-cells in the pathogenesis of RHD, highlighting a need to ensure that any GAS vaccine candidate contains promising immunoprotective antigens/epitopes while excluding epitopes that cross-react with human tissues.
52. Guilherme L, Oshiro SE, Fae KC, Cunha-Neto E, Renesto G, Goldberg AC, Tanaka AC, Pomerantzeff PM, Kiss MH, Silva C, Guzman F et al: T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun (2001) 69(9):5345-5351.
53. Wolfe CK Jr, Hayashi JA, Walsh G, Barkulis SS: Type-specific antibody response in man to injections of cell walls and M protein from group A, type 14 streptococci. J Lab Clin Med (1963) 61:459-468.
54. Fox EN, Waldman RH, Wittner MK, Mauceri AA, Dorfman A: Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest (1973) 52(8):1885-1892.
55. Polly SM, Waldman RH, High P, Wittner MK, Dorfman A: Protective studies with a group A streptococcal M protein vaccine. II. Challenge of volunteers after local immunization in the upper respiratory tract. J Infect Dis (1975) 131(3):217-224.
56. D'Alessandri R, Plotkin G, Kluge RM, Wittner MK, Fox EN, Dorfman A, Waldman RH: Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with type 3 or type 12 group A Streptococcus. J Infect Dis (1978) 138(6):712-718.
57. Bessen D, Fischetti VA: Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med (1988) 167(6):1945-1950.
58. Massell BF, Honikman LH, Amezcua J: Rheumatic fever following streptococcal vaccination. Report of three cases. J Am Med Assoc (1969) 207(6):1115-1119.
59. Brandt ER, Good MF: Vaccine strategies to prevent rheumatic fever. Immunol Res (1999) 19(1):89-103.
60. Good MF, Cleary PJ, Dale J, Fischetti V, Fuchs K, Sabharwal H, Zabriskie J: Development of a vaccine to prevent infection with group A streptococci and rheumatic fever. In: New Generation Vaccines, 3rd Edition. Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF (Eds), Marcel Dekker Inc, New York, NY, USA (2004):695-710.
61. Kotloff KL, Dale JB: Progress in group A streptococcal vaccine development. Pediatr Infect Dis J (2004) 23(8):765-766.
62. Dale JB, Chiang EY, Lederer JW: Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol (1993) 151(4):2188-2194.
63. Dale JB, Simmons M, Chiang EC, Chiang EY: Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine (1996) 14(10):944-948.
64. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB: Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun (2002) 70(4):2171-2177.
65. Dale JB, Penfound T, Chiang AY, Long V, Shulman ST, Beall B: Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol (2005) 12(7):833-836.
66. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB: Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults. Phase 1 trial. J Am Med Assoc (2004) 292(6):709-715.
67. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J et al: Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin Infect Dis (2005) 41(8):1114- 1122. •• This paper describes a clinical trial of a subunit recombinant GAS M-protein-based vaccine in humans. The vaccine consists of a mixture of four different recombinant proteins designed using a type-specific approach to incorporate amino terminal peptide epitopes from M proteins of 26 common pharyngitis, invasive and/or rheumatogenic serotypes.
68. Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB: Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun (2004) 72(5):2507-2512.
69. Shulman ST, Stollerman G, Beall B, Dale JB, Tanz RR: Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis (2006) 42(4):448-450.
70. Pruksakorn S, Sittisombut N, Phornphutkul C, Pruksachatkunakorn C, Good MF, Brandt E: Epidemiological analysis of non-M-typeable group A Streptococcus isolates from a Thai population in Northern Thailand. J Clin Microbiol (2000) 38(3):1250-1254.
71. Dey N, McMillan DJ, Yarwood PJ, Joshi RM, Kumar R, Good MF, Sriprakash KS, Vohra H: High diversity of group A streptococcal emm types in an Indian community: The need to tailor multivalent vaccines. Clin Infect Dis (2005) 40(1):46-51.
72. Brandt ER, Teh T, Relf WA, Hobb RI, Good MF: Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun (2000) 68(12):6587-6594.
73. Fischetti VA, Hodges WM, Hruby DE: Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science (1989) 244(4911):1487-1490.
74. Bolken TC, Franke CA, Jones KF, Bell RH, Swanson RM, King DS, Fischetti VA, Hruby DE: Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by Gram-positive commensal vectors. Infect Immun (2002) 70(5):2487-2491.
75. Kotloff KL, Wasserman SS, Jones KF, Livio S, Hruby DE, Franke CA, Fischetti VA: Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A Streptococcus vaccine. Infect Immun (2005) 73(4):2360-2366.
76. Mannam P, Jones KF, Geller BL: Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun (2004) 72(6):3444-3450.
77. Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, Hunsakunachai S, Manmontri A, Good MF: Towards a vaccine for rheumatic fever: Identification of a conserved target epitope on M protein of group A streptococci. Lancet (1994) 344(8923):639-642.
78. Relf WA, Cooper J, Brandt ER, Hayman WA, Anders RF, Pruksakorn S, Currie B, Saul A, Good MF: Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept Res (1996) 9(1):12-20.
79. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF: Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A Streptococcus. Int Immunol (1997) 9(11):1723-1733.
80. Bessen D, Fischetti VA: Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun (1988) 56(10):2666-2672.
81. Bronze MS, Courtney HS, Dale JB: Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol (1992) 148(3):888-893.
82. Bessen D, Fischetti VA: Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol (1990) 145(4):1251-1256.
83. Wiesmuller KH, Bessler W, Jung G: Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N- palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe Seylers Z Physiol Chem (1983) 364(5):593-606.
84. Toth I, Danton M, Flinn N, Gibbons WA: A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilizing lipidic amino acids. Tetrahedron Lett (1993) 34:3925-3928.
85. Tam JP: Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA (1988) 85(15):5409-5413.
86. Horváth A, Olive C, Wong A, Clair T, Yarwood P, Good M, Toth I: Lipoamino acid-based adjuvant carrier system: Enhanced immunogenicity of group A streptococcal peptide epitopes. J Med Chem (2002) 45(6):1387-1390.
87. Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF: Potential of lipid core peptide technology as a novel selfadjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun (2003) 71(5):2373-2383.
88. Olive C, Batzloff MR, Horváth A, Wong A, Clair T, Yarwood P, Toth I, Good MF: A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun (2002) 70(5):2734-2738.
89. Olive C, Sun HK, Ho M-F, Dyer J, Horvath A, Toth I, Good MF: Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis (2006) 194(3):316-324. •• This was the first study showing the effectiveness of the LCP system to deliver GAS vaccine M protein antigens intranasally in order to elicit protective mucosal immune responses against GAS without the need for an additional mucosal adjuvant.
90. Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP: Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS (2006) 20(7):1039-1049.
91. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 342(6249):561-564.
92. Mora AL, Tam JP: Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. J Immunol (1988) 161(7):3616-3623.
93. Nardelli B, Haser PB, Tam JP: Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine (1994) 12(14):1335-1339.
94. Zeng W, Jackson DC, Murray J, Rose K, Brown LE: Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. Vaccine (2000) 18(11-12):1031-1039.
95. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A, Druilhe P: Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol (1997) 27(5):1242-1253.
96. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF: Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved peptide, a universal T-cell epitope, and a self-adjuvanting lipid protects mice from group A Streptococcus challenge and reduces throat colonization. J Infect Dis (2006) 194(3):325-330.
97. Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, White G, Burt DS, Leanderson T, Good MF: Toward the development of an antidisease, transmission-blocking intranasal vaccine for group A Streptococcus. J Infect Dis (2005) 192(8):1450-1455.
98. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH: Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun (2001) 69(7):4545-4553.
99. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER, Good MF: Protection against group A Streptococcus by immunization with J8-diptheria toxoid: Contribution of J8- and diptheria toxoid-specific antibodies to protection. J Infect Dis (2003) 187(10):1598- 1608.
100. Olive C, Clair T, Yarwood P, Good MF: Protection of mice from group A streptococcal infection by intranasal immunization with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T-cell autoepitope. Vaccine (2002) 20(21-22):2816-2825.
101. Jackson DC, O'Brien-Simpson N, Ede NJ, Brown LE: Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine (1997) 15(15):1697-1705.
102. Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR, Jackson DC, Good MF: New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med (2000) 6(4):455-459.
103. Horvath A, Olive C, Karpati L, Sun HK, Good M, Toth I: Towards the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage. J Med Chem (2004) 47(16):4100-4104.
104. Olive C, Ho M-F, Dyer J, Lincoln D, Barozzi N, Toth I, Good MF: Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A Streptococcus. J Infect Dis (2006) 193(12):1666-1676. •• This study demonstrates the feasibility of incorporating multiple peptide epitopes into the LCP system in a defined order, without loss of immunogenicity or protective potential. An LCP was synthesized containing four M protein peptide epitopes and was highly immunogenic, eliciting serum IgG peptide-specific responses when administered parenterally to mice in the presence or absence of complete Freund's adjuvant.